The prevalence of most PNSs is very low, but symptoms often precede discovery of the cancer. Thus, diagnosis of a PNS and its cause can lead to earlier cancer treatment and better chances of good cancer-related outcomes. However, because PNS-associated antibodies may cause permanent damage, successful treatment of a tumor does not always result in neurologic improvement.
The exact mechanisms of autoantibody-caused dysfunction in PNSs are often unclear. For extracellular antigens (eg, channels and receptors), pathogenesis may involve interference with synaptic transmission. For intracellular antigens, pathogenesis may involve T-cell mediated cellular immunity.
Diagnosis can be complicated because signs and symptoms of the different syndromes overlap. In addition, autoimmune neurological syndromes are not always paraneoplastic (ie, caused by cancer); they can be caused by infectious agents, toxins, or metabolic conditions. The diagnosis of a PNS and identification of an underlying malignancy can involve imaging and laboratory tests. 3 Laboratory tests can identify specific autoantibodies that indicate possible PNSs and can guide the search for an underlying malignancy. However, a single antibody can be associated with multiple syndromes and cancer types, and a single syndrome or cancer type can be associated with multiple antibodies. Furthermore, these antibodies can occur in the absence of an underlying cancer; that is, they are also associated with non-paraneoplastic conditions, such as autoimmune encephalitis, rapidly progressing dementia, and epilepsy. Testing for many autoantibodies at the same time may be appropriate in certain clinical circumstances. 4 This Clinical Focus discusses the role of autoantibody testing in the diagnosis of PNSs and associated cancer and tumor types. It is intended as an overview; thus, it focuses on studies involving larger cohorts and generally does not discuss case reports unless necessary. Complete diagnostic criteria, prognosis, follow-up studies, and treatment options (eg, immune modulation) of PNSs are beyond the scope of this Clinical Focus. These topics are covered in review articles and guidelines. [1] [2] [3] [4] 
INDIVIDUALS SUITABLE FOR TESTING
• Individuals who have signs and symptoms consistent with a PNS (Table 1) • Individuals who have a PNS with an unidentified underlying malignancy
TEST AVAILABILITY AND SELECTION
If a specific syndrome is suspected based on the clinical presentation, individual antibody tests may help identify the presence of an underlying malignancy. However, the European Federation of Neurological Societies (EFNS) Task Force points out that most syndromes and tumors are associated with multiple antibodies. Thus, the EFNS recommends testing for several antibodies simultaneously to avoid the loss of time to diagnosis and improve the testing yield. 4 Quest Diagnostics offers several tests and panels ( Table 2 for some patients, detection of antibodies in CSF is more robust than in serum [5] [6] [7] [8] • Autoimmune Neurology Antibody Comprehensive Panel with Reflexes, Serum (test code 93888, Figure 3 ): for use with serum specimens
Many, but not all, antibody tests are available individually ( Table 2) ; some tests are only offered as components of line blots or mosaics. If a clinician would like to order individual tests related to a particular syndrome or cancer type, Table 3 and information in the Test Interpretation section can help identify which antibodies would be most appropriate. Table 3 includes PNS-related antibodies and associated syndromes and cancer types. The Test Interpretation section contains information about the antibodies. 
TEST INTERPRETATION
The presence of an antibody is associated with certain PNSs and malignancies (see Table 3 and below). However, antibodies and syndromes can occur in the absence of cancer or a tumor and are associated with other non-paraneoplastic conditions, such as autoimmune encephalitis, rapidly progressing dementia, and epilepsy. To confirm the presence of an underlying malignancy, positive antibody test results must be followed with imaging (eg, computed tomography The absence of an antibody rarely confirms the absence of an associated syndrome or cancer type. • 
AChR (acetylcholine receptor)
A positive test result for AChR antibody is consistent with myasthenia gravis (MG). Thymoma is the most commonly associated tumor type.
Among patients with MG, 79% to 85% test positive for AChR antibody. 11, 12, 25 Among patients confirmed as not having MG (but initially suspected of having MG), 0% test positive, indicating 100% specificity for MG. 12 In side-by-side comparisons with other MG-related antibodies (ryanodine receptor [RyR] , striated muscle, and titin), 11, 12 AChR antibody was generally more sensitive for thymoma in MG patients, though one study demonstrated a 95% sensitivity for titin antibody. 11 However, AChR antibody was less specific than RyR, striated muscle, or titin antibodies (Table 4) . 11, 12 Three types of AChR antibodies, which affect receptors in different ways, can help with MG diagnosis: binding, modulating, and blocking. Binding antibodies are present in 69% to 82% of patients with generalized MG. 26 Modulating antibodies are found at approximately the same frequency, but ~4% of patients test positive for modulating antibody and negative for binding antibody. Thus, testing for modulating antibody may help identify more patients with MG. Blocking antibody is present in <1% of patients without binding antibodies and is rare in non-MG diseases; thus, it can confirm binding antibody positivity and improve specificity.
AGNA/SOX1 (anti-glial nuclear antibody)
A positive test result for AGNA/SOX1 is consistent with Lambert-Eaton myasthenic syndrome (LEMS), sensory neuropathy, limbic encephalitis, and cerebellar degeneration. Small-cell lung cancer (SCLC) is the most commonly associated cancer type.
In a study of 24 patients who tested positive for AGNA, 38% had LEMS, 21% had paraneoplastic cerebellar degeneration (of those, 1 patient also had LEMS), 13% had sensory neuropathy, 8% had limbic encephalitis, and 4% had sensorimotor neuropathy; 17% did not have a PNS. Of the 24 patients, 92% had lung cancer (79% had SCLC). 16 In patients who have SCLC but no PNS, 22% to 32% test positive for AGNA. 27, 28 AGNA/SOX1 can be particularly useful for identifying SCLC in patients with LEMS. In patients with LEMS, 43% to 64% of those with SCLC test positive for AGNA, whereas 0% of those without SCLC test positive. 16, 27 Thus, in a patient with LEMS, a positive AGNA result is consistent with SCLC, while a negative result suggests absence of SCLC.
AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor)
A positive test result for AMPAR antibody is consistent with limbic encephalitis. Lung (SCLC), thymoma, breast, and ovarian cancer types are associated with AMPAR antibody.
Among patients with suspected PNS, 0.2% test positive for AMPAR antibody. 17 In a study of 22 AMPAR antibody-positive patients, 13 (59%) had limbic encephalitis and 8 (36%) had limbic dysfunction and encephalopathy; the remaining patient had psychosis with bipolar features. Cancer was identified in 14 (64%) of patients: 6 had lung cancer (5 had SCLC), 4 had thymoma, 2 had breast cancer, and 2 had ovarian teratoma. 17 In a study of 109 patients who had limbic encephalitis, 10 (9%) tested positive for AMPAR antibody. Of these, 7 had neoplasms: 3 had thymus cancer, 2 had breast cancer, and 2 had lung cancer. 29 
Amphiphysin
A positive test result for amphiphysin antibody is consistent with sensory neuropathy, encephalomyelitis/limbic encephalitis, and stiff-person syndrome. SCLC and breast cancer are the most commonly associated cancer types.
Among patients with suspected PNS, 0.06% test positive for amphiphysin antibody. 21 Among patients who test positive, 52% present with neuropathy, 30% with encephalopathy, 29% with encephalomyelitis with rigidity, 27% with myelopathy, 22% with generalized or focal pain, and 17% with cerebellar syndrome. Other conditions associated with amphiphysin antibody include Lambert-Eaton syndrome, opsoclonus, cranial neuropathies, optic neuritis/retinitis, and pruritus. 21 Amphiphysin antibody has also been reported in patients with stiff-person syndrome, though GAD antibody is much more common in those patients. 19 21 Ovarian cancer has also been reported, but at a much lower rate than SCLC and breast cancer. 30 Other PNS-related antibodies coexist with amphiphysin in a substantial proportion of patients (38% to 70%). CRMP5/CV2, ANNA1, and voltage-gated calcium channels are the most frequently coexisting antibodies. 21, 31 ANNA1 (Hu; anti-neuronal nuclear antibody type 1)
A positive test result for ANNA1 is consistent with sensory neuropathy, cerebellar ataxia, limbic encephalitis, brainstem encephalitis, and autonomic neuropathy. SCLC is the most commonly associated cancer type.
Among patients with suspected PNS, 0.4% test positive for ANNA1 antibody. 31 In patients with confirmed PNS and ANNA1, 54% to 86% have neuropathy, 11% to 22% have cerebellar syndromes, 10% to 21% have limbic syndromes, 6% to 18% have brainstem syndromes or encephalitis, and 4% to 24% have dysautonomia. 15, 32, 33 Cancer develops in 80% to 98% of patients who test positive. 15, 31 In 80% to 86% of cancer patients with ANNA1, cancer is found in the lung (SCLC develops in 66% to 82%). 15, [31] [32] [33] Cancer in the bladder, breast, gastrointestinal tract, pancreas, prostate, or ovary each develop in 1% to 4% of patients. 15 ANNA1 coexists with other PNS-related antibodies in 43% of patients. Antibodies to CRMP5/CV2, P/Q-type voltage-gated calcium channels (VGCC), or N-type VGCC coexist in 14% to 17% of ANNA1-positive patients. Other antibodies coexist at frequencies between 1% and 5%. 31
ANNA2 (Ri, anti-neuronal nuclear antibody type 2)
A positive test result for ANNA2 is consistent with opsoclonus-myoclonus and cerebellar syndrome. Lung and breast cancers are the most commonly associated cancer types. Gynecological tumors are also associated but much less commonly. 34, 35 Among patients with suspected PNS, 0.05% test positive for ANNA2. 20 In a study that included 34 patients who tested positive, 59% presented with manifestations indicating brainstem involvement (eg, ataxia, opsoclonus-myoclonus), and 41% presented with manifestations indicating cerebellum involvement (eg, ataxia with nystagmus). Lung cancer occurred in 36% of ANNA2-positive patients, breast cancer in 32%, and other cancer types in 15%. 20 Among patients who test positive for ANNA2 antibody, 35% also test positive for other PNS-related autoantibodies, most commonly ANNA1, GAD65, P/Q-type VGCC, or N-type VGCC. 20,31
ANNA3 (anti-neuronal nuclear antibody type 3)
A positive test result for ANNA3 is consistent with sensory neuropathy and limbic encephalopathy. SCLC is the most commonly associated cancer.
In a study of 68,000 patients with suspected PNS, 11 (0.02%) tested positive for ANNA3. ANNA3 was not present in any control patients (ANNA1-positive, ANNA2-positive, healthy, SCLC-positive but negative for neurological disorder). In the 11 ANNA3-positive patients, neurological presentations were often multifocal and included sensory neuropathy, limbic encephalopathy, cerebellar ataxia, and myelopathy. Oncological information was available for 9; all 9 had cancer: 5 had SCLC, 2 had adenocarcinomas (lung, esophagus), 1 had a lung mass, and 1 had thoracic and abdominal masses. 9 Six of the 11 patients also tested positive for other PNSrelated antibodies: VGCC (3), gAChR (2), or ANNA2 (1). 9
Aquaporin 4 (NMO)
A positive test result for aquaporin 4 antibody is consistent with neuromyelitis optica (NMO)-spectrum disorders; these disorders involve demyelination in the central nervous system and can be misdiagnosed as multiple sclerosis. Many types of cancer have been observed in aquaporin 4 antibody-positive patients.
Among patients tested for PNS-related antibodies, 0.02% test positive for aquaporin 4 antibody. Among those who test positive, 93% have NMO. 10 In a study that included 31 patients who tested positive for aquaporin 4 antibody, 9 (29%) had neoplasms diagnosed: 3 with breast, 2 with lung, 1 with thymic, 1 with cervical, 1 with seminoma, bladder, and B-cell lymphoma, and 1 with monoclonal gammopathy. Notably, 2 of the 9 patients with neoplasms (1 with breast cancer and 1 with lung cancer) did not have clinical evidence of NMO. 10
CASPR2 (contactin-associated proteinlike 2)
See VGKC (voltage-gated potassium channel) section.
CRMP5/CV2 (collapsin response mediator protein 5)
A positive test result for CRMP5/CV2 antibody is consistent with multiple PNSs: sensory neuropathy, cerebellar ataxia, autonomic neuropathy, limbic encephalitis, and chorea. SCLC and thymoma are the most commonly associated cancer types.
Among patients with suspected PNS, 0.2% test positive for CRMP5/CV2 antibody. Among patients who test positive, 47% to 57% display sensory neuropathy, 26% to 46% display cerebellar ataxia, 31% display autonomic neuropathy, 25% display subacute dementia, 14% display myasthenic syndrome (LEMS or MG), 14% display limbic encephalitis, 12% display neuromuscular junction disorders, and 11% display chorea. 23 In a study of 16 patients with paraneoplastic chorea, all patients tested positive for CRMP5/CV2. 26 Among CRMP5/CV2-positive patients, 53% to 77% have lung cancer (47% to 62% have SCLC) and 6% to 15% have thymoma. 23, 31, 32 CRMP5/CV2 antibodies rarely occur in healthy individuals (0.6%) but occur in 5% of patients with SCLC and 12% of patients with thymoma. 37 Among patients who test positive for CRMP5/CV2, 57% also test positive for a range of other PNS-related antibodies; the most frequent antibodies are ANNA1 (17%), N-type VGCC (14%), and P/Q-type VGCC (13%). 31
DPPX (dipeptidyl-peptidase-like protein-6)
GABA B R (gamma-aminobutyric acid receptor B)
A positive test result for GABA B R antibody is consistent with limbic encephalitis. SCLC is the most commonly associated cancer type.
Among patients with suspected autoimmune encephalitis, 0.2% test positive for GABA B R antibody. 38 In a study that included 7 patients with suspected autoimmune encephalitis who tested positive for GABA B R antibody, all 7 were confirmed to have limbic encephalitis. Of these, 5 had SCLC and 1 had a lung mass that was not biopsied; the patient without cancer was 16 years old. 38 In a study that included 15 patients with suspected paraneoplastic encephalitis who tested positive for GABA B R antibody, 7 had tumors, 5 of which were SCLC. Of the 15 patients, 7 tested positive for antibodies to other antigens (N-type VGCC, GAD65, thyroid peroxidase, or thyroglobulin). 39
gAChR (ganglionic acetylcholine receptor)
A positive test result for gAChR antibody is consistent with multiple neurological presentations, including autonomic neuropathy, sensorimotor neuropathy, and cortical and neuropsychiatric manifestations. Many cancer types are associated with gAChR antibody.
Among patients tested for PNS-related antibodies, 1% test positive for gAChR antibody. 18 Among those who test positive, 28% have somatic peripheral manifestations, most commonly sensorimotor polyneuropathy; 21% have peripheral autonomic manifestations, most commonly limited dysautonomia, pandysautonomia, and GI dysmotility; 17% have central nervous system manifestations, most commonly cortical or neuropsychiatric. Manifestations are multifocal in 29% of patients. 18 In a study that included 78 gAChR antibody-positive patients, 24 (30%) had cancer, of which 6 had multiple malignant neoplasms. Eighteen types of cancer were observed. There were multiples cases of the following cancer types: 11 adenocarcinoma (breast [4] , prostate [3] , lung [2] , gastrointestinal [2] ), 5 lymphoid (B cell lymphoma [3] ), 2 renal cell carcinoma, 2 melanoma, and 2 bladder. 18 Small studies have also reported SCLC and thymoma. 40, 41 Coexisting antibodies are detected in 26% of gAChR antibodypositive patients: GAD65, muscle AChR, N-type VGCC, VKCC, P/Q-type VGCC, striational, ANNA1, and CRMP5/CV2. 18
GAD65 (glutamic acid decarboxylase 65 kD protein)
A positive test result for GAD65 antibody is associated with stiff-person syndrome, cerebellar ataxia or degeneration, and limbic encephalitis. Many cancer types are associated with GAD65 antibody. [42] [43] [44] Among patients who test positive for GAD65 antibody, 36% have stiff person syndrome, 33% have cerebellar ataxia or degeneration, and 7% have limbic encephalitis or encephalomyelitis. 42 Although many cancers have been described in GAD65 antibody-positive patients, most reports represent case studies or single patients within a larger study. Ariño and colleagues summarized findings from 34 GAD65 antibodypositive patients (15 newly identified and 19 previously reported). Of these, 10 had lung cancer (including 7 SCLC), 10 had thymoma (3 malignant), 6 had breast cancer, 4 had hematological cancer (2 non-Hodgkin lymphoma, 1 multiple myeloma, 1 Hodgkin lymphoma), and 4 had other cancers (2 pancreas, 1 kidney, 1 cavum). 43 GAD antibodies are also present in ~80% of patients with type 1 diabetes. 45 However, titers of GAD antibody are usually >100 times higher in patients with stiff-person syndrome than in those with type 1 diabetes. 46
LGI1 (leucine-rich glioma inactivated-1)
See VGKC (voltage-gated potassium channel) section. 
Ma2/Ta

Myelin-associated glycoprotein (MAG)
A positive test result for MAG antibody is consistent with sensory or sensorimotor neuropathy and monoclonal gammopathy of uncertain significance (MGUS).
Among patients with IgM monoclonal gammopathy, MAG antibody positivity is more frequent in those with neuropathy (56%) than those without (7% 
NMDAR1 (N-methyl-D-aspartate receptor)
A positive test result for NMDAR1 antibody is consistent with encephalitis with psychiatric manifestations, seizures, dyskinesias, dystonia, and autonomic instability. Ovarian teratoma is the most commonly associated cancer type.
In a study of 100 patients (91 women) with encephalitis and a positive NMDAR1 antibody test, all displayed psychiatric symptoms: unresponsiveness (88%), dyskinesias (86%, includes dystonia), seizures (76%), autonomic instability (69%), and hypoventilation (66%). Of the 98 patients with available clinical information, 59% had a tumor; 91% of the tumors were ovarian teratomas. The 2 males with tumors had a testicular teratoma or SCLC. 52
PCA1 (Yo; Purkinje cell cytoplasmic antibody type 1)
A positive test result for PCA1 is consistent with cerebellar degeneration. Breast and ovarian cancers are most commonly associated cancer types.
Patients with paraneoplastic cerebellar degeneration who test positive for PCA1 are almost always women. Among PCA1-positive patients with paraneoplastic cerebellar degeneration, 79% to 95% develop cancer 34, 53 ; ovarian cancer accounts for 43% to 47% of cancers and breast cancer accounts for 25% to 40%. 53, 54 Among patients who test positive for PCA1, 9% test positive for other autoantibodies (voltage-gated channel or acetylcholine receptor antibodies). 31
PCA2 (Purkinje cell cytoplasmic antibody type 2)
A positive test result for PCA2 is consistent with encephalomyelitis, limbic encephalitis, and cerebellar ataxia. Lung cancer (SCLC) is the most commonly associated cancer type.
Among patients with suspected PNS, 0.07% test positive for PCA2. 31 In a case series, 10 PCA2-positive patients had various neurological presentations, including brainstem or limbic encephalitis in 5 patients and cerebellar ataxia in 3. Lung malignancies were identified in 9 patients, 8 of whom had SCLC. 55 The high incidence of lung cancer in PCA2-positive patients is supported by a study that included 19 PCA2-positive patients with adequate clinical information. Of those patients, 15 (79%) had lung cancer (10 SCLC, 5 NSCLC). 31 Among PCA2-positive patients, 63% have coexisting PNSrelated antibodies: 44% have CRMP5, 14% have P/Q-type VGCC, 12% have ANNA1, 9% have N-type VGCC, 9% have VKGC, and 11% have amphiphysin, ANNA3, muscle AChR, or striated muscle. 31
PCA-Tr (DNER, Purkinje cell cytoplasmic antibody Tr)
A positive test result for PCA-Tr is consistent with cerebellar degeneration. Hodgkin lymphoma is the most commonly associated cancer type.
In a study of 28 patients who tested positive for PCA-Tr, 93% had cerebellar degeneration, 4% had chronic, mild cerebellar ataxia, and 4% had limbic encephalitis. Of the 28 patients, 89% had Hodgkin lymphoma diagnosed; no tumor was found in the other 11%. 56 A positive PCA-Tr test result may indicate the presence of both a cerebellar disorder and Hodgkin disease; in a study that looked at patients who had one or the other, none of the patients tested positive for PCA-Tr. 57 
Recoverin
A positive test result for recoverin antibody is consistent with cancer-associated retinopathy (CAR). SCLC is the most commonly associated cancer type.
In a study of 193 patients who had symptoms consistent with paraneoplastic or autoimmune retinopathy, 12 (6%) tested positive for recoverin antibody; all 12 of these patients had paraneoplastic retinopathy. 58 Of the recoverin antibodypositive patients, 6 had lung cancer (5 had SCLC) and 2 (17%) had endometrial cancer; other patients had breast, colon, or skin cancer. 58 In a study of 18 patients with CAR, all tested positive for recoverin antibodies (10 initially and all upon follow-up).
Of the 18 patients, 10 had lung cancer (7 had SCLC), 2 had prostate cancer, and 2 had thymoma. 52 Among patients with lung cancer (SCLC and NSCLC), 17% test positive for recoverin; only 1% of patients who are healthy or have nonmalignant pulmonary diseases test positive. 60
RyR (ryanodine receptor)
See striated muscle section.
Striated muscle
A positive test result for striated muscle, RyR, or titin antibodies, is consistent with MG. Thymoma is the most commonly associated tumor type. The European Federation of Neurological Societies (EFNS) Task Force considers titin antibody a biomarker for thymoma. 4 Among patients with MG, 34% to 58% test positive for striated muscle antibody, 14% test positive for RyR, and 30% to 34% test positive for titin antibody. 11, 12 Unlike AChR, which occurs in all patients with early-onset MG, late-onset MG, or thymoma, the frequencies of striated muscle, RyR, and titin antibodies vary by MG type: they are present more often in patients with thymoma ( Table 5) . 11 In side-by-side comparisons with AChR (Table 4) , 11, 12 sensitivity for thymoma in MG patients is generally lower for striated muscle, RyR, and titin antibodies (usually around 75%) compared to that of AChR (100%), though titin sensitivity has been shown to be as high as 95%. 11 In contrast, specificity for thymoma in MG patients is higher for these antibodies (58% to 97%) than that of AChR (17% to 23%).
Titin
VGCC, N-type (N-type voltage-gated calcium channel)
A positive test result for N-type VGCC antibody is consistent with LEMS. SCLC is the most commonly associated cancer type. 13 In a study that included 72 VGKC antibodypositive patients, 47% had suspected or histologically confirmed neoplasms; of the 12 types described, the most common were SCLC, adenoma, mass lesion or adenopathy, thymoma or thymic carcinoma, and prostate adenocarcinoma. 66 The epitopes recognized by VGKC autoantibodies are often on proteins bound to the calcium channels, such as LGI1, CASPR2, and DPPX. 
